4:30 PM - 4:45 PM (PDT), Monday, June 13, 2022
Salspera has emerged as a leader in the field of microbial immunotherapy. The company has created a platform of orally administered microbial immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. One of these therapies is Saltikva, an orally administered, unique, non-toxic cancer therapeutic that acts synergistically with conventional chemotherapy. Saltikva is an attenuated Salmonella Typhimurium containing the gene for human Interleukin-2. Recently, Saltikva was released on a compassionate basis to a patient with metastatic pancreatic cancer. With a median life expectancy of just 11 months, this patient is now in month 36 post-diagnosis, is feeling extremely well with complete resolution of her pulmonary metastases and significant diminution of her liver metastases and primary pancreatic cancer. A Phase II clinical study of Saltikva in metastatic pancreatic cancer is currently ongoing.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Saltikva (Salmonella-IL2)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief of Pediatric Surgery (U of MN Med School); Chief Medical Officer (Salspera)
University of Minnesota Medical School; Salspera